Senate Passes FDA Modernization Act 3.0, Expanding Drug Testing Beyond Animal-Only Experiments
The House must act next: House consideration.
This bill’s path across every version that has carried it.
How this policy affects specific groups of people
Held at the desk.
Received in the House.
The House has received the Senate-passed bill and will decide whether to take it up.
Message on Senate action sent to the House.
Passed Senate with an amendment by Unanimous Consent. (text of amendment in the nature of a substitute: CR S8794)
The Senate voted to approve this bill. If the House already passed it, it goes to the President.
Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.
The Senate voted to approve this bill. If the House already passed it, it goes to the President.
The FDA announced it will begin phasing out animal testing requirements for antibody therapies and other drugs, moving toward AI-based models and 'human-relevant' tools. The move follows the legislative push from the FDA Modernization Act to reduce reliance on costly and often inaccurate animal models.
FDA Commissioner Marty Makary announced a shift away from animal testing, a move directed by recent federal law. The agency will focus on monoclonal antibodies first, aiming to get treatments to patients faster while sparing primates and dogs from experiments.
The FDA announced plans to replace animal testing with AI-based computational modeling and human organ model-based lab testing. This approach follows the introduction of the FDA Modernization Act 3.0, intended to shore up implementation of previous reforms and reduce drug development costs.
No votes recorded for this bill yet.
Document Type
Congressional Bill
Official Title
FDA Modernization Act 3.0
Analysis generated by AI. Always verify with official sources.